Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …
for younger patients over the last several decades has improved nearly sixfold with the …
[HTML][HTML] RNA methylation and cancer treatment
To this date, over 100 different types of RNA modification have been identified. Methylation
of different RNA species has emerged as a critical regulator of transcript expression. RNA …
of different RNA species has emerged as a critical regulator of transcript expression. RNA …
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase …
CD DiNardo, AC Schuh, EM Stein… - The Lancet …, 2021 - thelancet.com
Background Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2)
proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus …
proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus …
Dynamic RNA modifications in gene expression regulation
Over 100 types of chemical modifications have been identified in cellular RNAs. While the
5′ cap modification and the poly (A) tail of eukaryotic mRNA play key roles in regulation …
5′ cap modification and the poly (A) tail of eukaryotic mRNA play key roles in regulation …
[HTML][HTML] R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling
Summary R-2-hydroxyglutarate (R-2HG), produced at high levels by mutant isocitrate
dehydrogenase 1/2 (IDH1/2) enzymes, was reported as an oncometabolite. We show here …
dehydrogenase 1/2 (IDH1/2) enzymes, was reported as an oncometabolite. We show here …
RNA N6-methyladenosine modification in cancers: current status and perspectives
Abstract N 6-methyladenosine (m6A), the most abundant internal modification in eukaryotic
messenger RNAs (mRNAs), has been shown to play critical roles in various normal …
messenger RNAs (mRNAs), has been shown to play critical roles in various normal …
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
K Morita, F Wang, K Jahn, T Hu, T Tanaka… - Nature …, 2020 - nature.com
Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection.
Precise characterization of clonal architecture is essential to understand the evolutionary …
Precise characterization of clonal architecture is essential to understand the evolutionary …
Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia
M Konopleva, DA Pollyea, J Potluri, B Chyla, L Hogdal… - Cancer discovery, 2016 - AACR
We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly
selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with …
selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with …
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
GC Issa, CD DiNardo - Blood cancer journal, 2021 - nature.com
Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy;
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …
Isocitrate dehydrogenase mutations in myeloid malignancies
BC Medeiros, AT Fathi, CD DiNardo, DA Pollyea… - Leukemia, 2017 - nature.com
Alterations to genes involved in cellular metabolism and epigenetic regulation are
implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate …
implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate …